Fyodor Biotechnologies

Fyodor Biotechnologies is a private, commercial-stage diagnostics company focused on transforming malaria detection through its innovative Urine Malaria Test (UMT). The test is rapid, accurate, non-invasive, and designed for home use, addressing key barriers to diagnosis in endemic regions. With a strong leadership team and validation from top-tier institutions, the company has achieved initial regulatory approvals in key African markets and is positioned to capture a significant share of the global malaria diagnostics market.

Platform for non-invasive, rapid diagnostic tests using urine samples to detect disease-specific antigens, initially validated for malaria.

Fyodor competes in the malaria RDT market dominated by large diagnostics companies (e.g., Abbott, SD Biosensor, Access Bio) offering blood-based tests. Its primary differentiation is non-invasiveness and home-use design, creating a new product category rather than directly competing on price in the traditional clinical market.